Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

August 31, 2007

Study Completion Date

August 31, 2007

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

Rituximab

DRUG

Aldesleukin

Trial Locations (21)

22031

Fairfax Northern VA Hem-Onc PC, Fairfax

23502

Virginia Oncology Associates, Norfolk

24153

Onc and Hem Associates of SW VA, Inc., Salem

29615

Cancer Centers of the Carolinas, Greenville

45409

Greater Dayton Cancer Center, Kettering

55404

Minnesota Oncology Hematology, PA, Minneapolis

60611

Hematology Oncology Associates of IL, Chicago

60714

Cancer Care & Hematology Specialists of Chicagoland, Niles

64111

Kansas City Cancer Centers-Central, Kansas City

75042

Texas Oncology, PA, Garland

75230

Texas Cancer Center at Medical City, Dallas

75601

Longview Cancer Center, Longview

75702

Tyler Cancer Center, Tyler

76014

Texas Cancer Center, Arlington

78624

San Antonio Tumor & Blood Clinic, Fredericksburg

79915

El Paso Cancer Treatment Ctr, El Paso

80218

Rocky Mountain Cancer Center-Midtown, Denver

98026

Puget Sound Cancer Center-Edmonds, Edmonds

98133

Pudget Sound Cancer Center-Seattle, Seattle

98902

Yakima Valley Mem Hosp/North Star Lodge, Yakima

99218

Cancer Care Northwest-North, Spokane

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Chiron Corporation

INDUSTRY

collaborator

Fred Hutchinson Cancer Center

OTHER

lead

US Oncology Research

INDUSTRY